Summary Xplico Valuation Survey

By |November, 2018|

Discount Rate versus Affiliation

In July and August 2018 Xplico conducted a survey among 600 industry professionals about valuation in the life science industry and received 79 responses. We hereby present the results of the survey.

PDF: Summary Xplico Valuation Survey – with graphs.

Xplico article for Biotech & Money / LSX

By |October, 2018|

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits:

Link to the article:

https://www.lsxleaders.com/blog/addressing-the-challenges-of-ownership-structures-in-life-sciences

Xplico named “a 2018 Gazelle Company” (a growth company) for the third year in a row by the leading Danish business newspaper Børsen.

By |October, 2018|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2018 Gazelle Company for the 3rd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years.

 

(September 2018)

Xplico article for Biotech & Money / LSX

By |August, 2018|

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Xplico is pleased to announce that Sisse Ramsing Escargueil has joined our team

By |August, 2018|

Xplico is pleased to announce that Sisse Ramsing Escargueil has joined our team as Executive Assistant and will be working closely together with the partners Uffe Boesen and Finn Nikolajsen.
Sisse holds a Master’s Degree in International Business Relations and has more than 18 years of experience from Sales Management (B2C and B2B) and Business Administration. She has previous experience as both Executive Assistant and Personal Assistant and has worked with business development, sales management, market analysis and financial research in Denmark, France and USA.

Xplico Interview with Biotech & Money / LSX

By |July, 2018|

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.
The link to the interview: Xplico: supporting strategic decision-making through life science valuations

Xplico named “a 2017 Gazelle Company” (a growth company) for the second year in a row by the leading Danish business newspaper Børsen.

By |February, 2018|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2017 Gazelle Company for the 2nd year in a row. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of four consecutive years. Further, the revenue needs to be doubled in the period of four years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years.

 

(September 2017)

Xplico named “a 2016 Gazelle Company” (a growth company) by the leading Danish business newspaper Børsen.

By |January, 2017|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2016 Gazelle Company. Børsen analyses every year all the Danish companies to identify growth companies. A Gazelle company is defined by the growth in revenue every year for a minimum of 4 consecutive years. Further, the revenue needs to be doubled in the period of 4 years and the company must generate a profit. We plan to stay on the Gazelle list for the coming years.
(September 2016)

Xplico is pleased to announce that Peter Abelin has joined our valuation team.

By |January, 2017|

Xplico is pleased to announce that Peter Abelin has joined our valuation team.
Peter has more than 25 years’ experience from the life science industry working with equity portfolio management, financial research and pharmaceutical development at Swedbank Robur, AMF Pension, SEB Enskilda, Astra AB and as an MD. Peter brings a lot of expertise in assessing equity investments and life science equity valuation and will work closely with our clients valuating their business. Peter has combined his MD with BSc Econ and CE Financial Analyst.

skaermbillede-2017-01-04-kl-16-01-04
(June 2016)

Xplico launches Xplico Captable – a cap table providing simulations and waterfall analysis of the various stakeholders’ investments and values in a company.

By |January, 2017|

Xplico Captable is a capitalization table providing simulations and waterfall analysis of the founders’ and investors’ percentage of ownership, equity dilution, and value of equity in connection with (potential) funding rounds and exits. Xplico Captable has been successfully tested and reviewed by a number of companies including 2 of the Big 4 accounting companies. Xplico Captable is a very flexible and easy to use Excel-based tool and can be managed with very limited training. We ensure you the necessary support and backup as part of our Xplico Captable Package.

(January 2017)